Abstract-Heart failure (HF) is a complex syndrome which can be the exit of different etiologies which lead to a common clinical picture. Treatment outcome is modest and new insights into pathophysiology are needed to improve effectively diagnosis, prognosis, and therapy. As a complex disease, it can really benefit from the new approach provided by molecular medicine where information about the cell program can deeply change the patient management. The comprehension of molecular mechanisms relies on new technologies which are able to provide data at the different levels of the cell workflow. A proper processing of these data is as essential as the generation of data itself, together with an integrative approach able to exploit observations at different scales, starting from the molecular levels up to an effective assessment of phenotype with cardiovascular and systemic parameters. In this paper, evidences concerning current understanding of HF, passing from one scale to another, are reported, to underline how functional genomics and systems biology perspective, fostered by the combination of biotechnologies and bioinformatic methods, may transform the concepts of diagnosis and, consequently, of treatment, toward the fulfillment of the invoked patient-specific medicine.
The essential cause of HF is attributed to a loss of function of cardiomyocytes which reply to some stress and/or exceptional loading by reprogramming their gene expression, especially as concerns genes involved in metabolism, ions handling, and the reuse of genes which are specific of the fetal development [3] . This physiological response may trigger a positive feedback, overloading the cardiomyocytes leading eventually to cardiac dysfunction, as outlined in Fig. 1 . At the early stages of disease progression, functional capacity of the patient is preserved through compensatory neurohormonal mechanisms as the activation of the adrenergic nervous system, of the reninangiotensin-aldosterone system, the nonosmotic release of arginine vasopressin, the secretion of natriuretic peptides, endothelial hormones, nitric oxide, and cytokines [4] , [5] . As a consequence, the myocardium develops hypertrophy and interstitial fibrosis [6] due to alterations of the extracellular matrix, undergoing a remodeling process. The long-term activation of these compensatory mechanisms, which initially are able to preserve hemodynamic homeostasis, lead progressively to cardiac dilation and decrease of contractility till the "decompensated" stage and the precipitation of HF symptoms.
Although the "neurohormonal model" can depict a convincing explanation of disease progression, a more detailed scenario of the molecular landscape underlying HF is required to improve the current therapeutic strategies.
The advent of molecular medicine can shed light on the fundamental mechanisms which lead to HF, exploiting the information at the cellular level to understand the underlying mechanisms of cardiomyopathy [7] , [8] , transforming the concepts of diagnosis and, consequently, of treatment, toward the so-called personalized medicine. Indeed, the genomics and systems biology perspective fed by data produced by the new technologies together with the development of adequate computational approaches, may provide new insights into HF pathophysiology leading to new and more specific therapeutics. 
II. GENETICS AND FUNCTIONAL GENOMICS

A. Inherited Forms of HF
Traditionally, genetic forms of HF are distinguished from the so-called acquired forms. The former category encompasses familial dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. Genes whose mutations (see Table I ) can cause these inherited forms were found mainly by means of linkage analysis or candidate gene association studies on neurohormonal pathways and encode proteins that have a role in generation and transmission of contractile force (sarcomere proteins, cytoskeletal proteins, desmosome proteins, lamin A/C protein, whose mutations are the most frequent in DCM patients (with a percentage of 7.3%), energy production (mitochondrial proteins), calcium handling, transcription regulation [9] .
However, it was observed that mutations in the same genes can lead to different forms of familial cardiomyopathy [10] , [11] , demonstrating that single mutations may be not specific and completely explanatory of the phenotype and a more complex portrait is needed to characterize the triggered molecular response.
B. Transcriptomics
What is apparent at a clinical level in the disease progression (with signs as myocardium hypertrophy and interstitial fibrosis) is actually the outcome of a reprogramming of gene expression, which represents the physiological response of myocytes to stress conditions. So, a detailed analysis of the transcriptome becomes of paramount importance to study and characterize the myocardial tissue at the molecular level, unveiling genes and pathways which are perturbed in inherited and acquired forms of disease [12] .
Starting from the beginning of the new century, gene expression studies have been presented aimed at the characterization of HF dysregulome [13] , [14] . Tan et al. [15] compared oligonucleotide microarrays-based profiles of eight failing (tissue extracted from the left-ventricle of explanted hearts of transplant recipients) and seven nonfailing (organ donors) human hearts. The analysis allowed to identify a signature of differentially expressed genes in HF where atrial natriuretic factor and brain natriuretic peptide (BNP) were the most up-regulated genes, consistently with the known biomarkers. And consistently with the known myocytes reversal to a fetal program, α-actin was found down-regulated whereas myosin heavy chain-β was found up-regulated. Due to the remodeling process, deregulation of genes encoding extra-cellular matrix and cytoskeleton proteins, involving fibromudulin, t-plastin, fibronectin and desmosome-associated, was reported together with a significant increase of collagen types I and III responsible for myocardial tissue stiffness and deterioration. Moreover, genes involved in proteolysis and stress response, as thrombospondin-4, were found up-regulated. Genes belonging to metabolism pathways were differentially expressed, showing an overall downregulation attributable to fatty acid metabolism and an overexpression of genes involved in glucose metabolism. Consistently with the known loss of cardiomyocytes in HF, a downregulation of antiapoptotic genes emerged. Up-regulation of two ligands of the transforming growth factor (TGF)-β1 was found significant; it is, indeed, considered a crucial regulator of remodeling [6] ; overexpression of TGF-β1 in transgenic mice was shown to be causative of interstitial fibrosis and myocytes hypertrophy.
Along with confirmations of known findings, gene expression profiling improved the characterization of the genetic pathways involved in the physiopathology, at least as the used experimental platform, which is now obsolete, allowed. Unsupervised clustering techniques, specifically k-means algorithm, was used to group gene expression profiles across the samples, based on the assumption that genes that appear to be coregulated may contribute to the same process and unveil novel relationships; this allowed to override the univariate differential analysis and group genes combining functional annotations and expression patterns.
A hierarchical clustering algorithm was also applied to profiles across both the clinical samples and the genes identified as significant in differential analysis, obtaining the reorganized heatmap reported in Fig. 2 , where healthy and pathological samples are correctly discriminated, confirming the informativeness of the signature identified. Interestingly, the samples F3 and F5 which segregate away from the other pathological samples have a different etiology: F5 was an inheritable form of HF and F3 cardiomyopathy was due to alcoholism.
Several studies on HF have been proposed based on gene expression data of heart tissue but, due to obvious limitations, murine models are widely used to characterize the physiopathology in terms of gene expression and regulation [16] , [17] . Efforts toward the integration of gene expression profiles with phenotypic information at the system level have been shown, for example, with the identification of HF-associated genes correlated with clinical parameters such as pulmonary artery pressure and ejection fraction [18] . As said, myocardial gene expression studies are very important to unveil the pathophysiology mechanisms; on the other hand, for a disorder like HF, whose nature is obviously systemic, peripheral blood transcriptomics can provide important information, which can be applied at different levels of patient management, from diagnosis, to prognosis, monitoring, and treatment personalization. Van Buren et al. have recently identified a peripheral blood gene expression signature significantly associated with outcomes in HF patients [19] .
Still in peripheral blood, a signature of seven genes was recognized as a predictor of early stage (asymptomatic) HF, which can be diagnosed only by echocardiography; such a result may represent a useful tool for large screening of population at risk [20] .
Large-scale gene expression experiments are generally accomplished on samples representing a population of cells. Current approaches in transcriptomics (microarrays or RNA-seq) rely on measurements of RNA molecules pooled from a large number of cells. However, individual cells may exhibit a considerable heterogeneity in the expression of genes and their protein products. Monitoring molecular abundances of many distinct cells can unveil diversity of cell states and circuits and inherent stochastic variation, improving our comprehension of functional genomics both in physiology and in pathophysiology [21] . The acquisition of single cell spatial-temporal patterns has a great potential for data analytics and modeling and offers great challenges on the technological side for developing efficient experimental platforms along with adequate low-level data processing [22] [23] [24] .
C. Genetics versus Genomics
Moving from genetics, with the analysis of the genomic sequences interindividual variability, to transcriptomics adds a powerful layer of information. Processing expression data shows that different initial events (as hypertension, myocardial infarction, coronary artery disease, single gene mutations) can lead to a common response in terms of cell program and, at the same time, can allow the identification of specific signatures able to discriminate HF subtypes which would be indistinguishable at the clinical level. Addressing the inherent heterogeneity of a complex syndrome such as HF by means of molecular profiling is an important challenge in molecular medicine. This approach, for example, has already proven to be successful and is currently widely applied in cancer genomics.
The study of the genomic program, with the characterization of what the cell is really expressing and with the specification of the molecular determinants involved in the disease progression, is essential to reach a deep comprehension of the HF pathophysiology, allowing new target discovery and etiological (and consequently therapeutic) subtypes identification.
Looking at sporadic HF as a complex disease, it can be worth studying the contribution of genetic risk factors which can modulate the risk of developing acquired HF [25] . Modern high throughput technologies (genomewide SNP detection and deep sequencing platforms) allow to genotype subjects very efficiently providing the data to derive associations between alleles and pathology at a genome-wide level. In this direction, some studies have been presented. However, it can be observed that many of these associations have not been replicated and the ORs are rather low [26] . Moreover, sometimes the mutation identified belongs to a genomic position which is not clearly characterized from a functional point of view.
However, even if these mutations do not cause disease, they may modulate HF risk (see Fig. 3 ), progression and therapeutics responsiveness. Moreover, their identification can pinpoint the different functional elements of the genome which are involved in the myocardial response to overload, influencing the balance between a compensatory response and a progressive limitation of cardiac function.
Actually, genetic forms of HF, where single gene mutations are able to trigger the development of the disease, and acquired forms of HF (due, for example, to hypertension, myocardial infarction, etc.) lead to the same cardiac response whose fate and severity can be modulated by individual variability in genomic sequences.
It is interesting to note that many genes whose mutations are known causes of HF do not show deregulated expression levels in failing hearts. This contraposition between genetics and genomics might be solved hypothesizing that some genetic factors may trigger the overload of the myocardium, whose response determines changes in the expression of different genes. In this more comprehensive perspective, even the classification in inherited and acquired forms could be overcome.
This has been already observed discussing the general lack of overlap between genes harboring mutations and dysregulated genes and its possible explanation in the gene network context, arguing that mutated genes may be considered as upstream determinants while genes, whose expression is altered, are in general downstream effectors in the economy of the perturbed pathway.
D. Opportunities for Gene Expression Regulation
As seen, the elicitation of the functional elements of the genomic cell program and their mutual interactions in a systems biology perspective is indispensable. New technologies along with adequate bioinformatic approaches are essential and may help in redefining [27] HF in the postgenomic era. The study of the genome along with progresses in transcriptomics revealed that only a small portion of it is transcribed into protein coding mRNAs in vertebrates. However, the human transcriptome involves almost the 90% of the genome due to many different types of noncoding RNAs, whose classification is still unclear. Thus, complexity of higher organisms must be searched for not in the limited number of protein coding genes (about 22 000 for humans, but more than 20 000 also for the nematode Caenorhabditis Elegans) but rather in their fine regulation in time and space (different tissues) which noncoding RNAs and mechanisms of transcript processing (alternative splicing) contribute to.
1) MicroRNAs (miRNAs): miRNAs are important gene expression regulatory elements and as such their role in the pathogenesis and progression of cardiac disease and HF has been recently emerging [28] . MiRNAs are small noncoding RNAs (about 22 nucleotides in length) that inhibit expression of target genes by sequence-specific binding to the 3 untranslated region of messenger RNA, determining its degradation or translational repression. MiRNA genes may be intergenic or intronic and are generally subject to the same transcriptional regulation of protein coding genes. Their transcripts (pri-miRNAs) are processed and folded in a 70-100 nucleotides long hairpin precursor (pre-miRNA), which is then exported to the cytoplasm and cut to obtain two separate strands: the mature miRNA and its complementary version which is often nonfunctional and led to degradation. The nucleotides 2-8 at the 5 end of the mature miRNAs are referred to as "seed," as this portion of the sequence is fundamental in target recognition (an example is reported in Fig. 4 ). More than 2000 miRNAs are currently known in the human genome (as shown in the public dedicated repository miRBase) and are estimated to regulate more than half of protein coding genes. It is worth underlying that one transcript may contain binding sites for different miRNAs which act in combination and one single miRNA may target hundreds of genes influencing entire pathways.
The modulation of gene expression accomplished by miRNAs has been revealed as fundamental in cell development and tissue specification, indeed most targets belong to genes involved in cell-specific processes and, conversely, housekeeping genes are less subject to miRNAs action.
Differential expression of miRNAs can result in the consequent altered expression of direct (or indirect) targets, but it has also been suggested that they can exert a "buffering" function limiting excessive fluctuations of their targets (and conferring robustness to the cellular program) thanks to ad hoc positions in the gene circuitry.
Also the functional characterization of miRNAs within the human genome requires the development and the application of adequate bioinformatic approaches. The comprehension of the rules for miRNA-directed targeting of mRNAs relies on sequence analysis accomplished through pattern recognition methods, comparative genomics to identify phylogenetically conserved sites, structural accessibility analysis of the mRNA molecule, but also on gene expression data integration and systems biology approaches to study interactions on small and large scale. The development of target prediction strategies is still a major challenge in bioinformatics and computational genomics. Current predictors have a low level of accuracy and show a limited overlap in their results.
So far, many miRNAs (and many of their potential targets), which are involved in cardiac disease and HF development have been identified [28] . Experimental evidence of miRNA dysregulation was provided in relation to the different pathological processes characterizing HF, such as hypertrophy, fibrosis, remodeling, calcium handling changes.
For example, the first study reporting on miRNA expression showed that the overexpression of a combination of miRNAs upregulated in two murine models of HF was sufficient to induce hypertrophy in cardiomyocytes [29] .
MiR-208 represents another interesting example, it is expressed exclusively in cardiac tissue and its silencing in MiR-208 knock-out mice resulted in a protective effect against pressure overload-induced hypertrophy and, conversely, cardiac specific overexpression of miR-208 determined a hypertrophic response. Successively, the therapeutic silencing of miR-208 a via subcutaneous delivery of a specific oligomer able to establish specific binding was shown to be effective in rats, preventing remodeling and myocyte functional degeneration [30] . This is an important result showing the potential of miRNAs as novel therapeutic targets for heart.
MiRNAs are present not only in the cytoplasm but also outside cells, in body fluids. The expression of miRNAs circulating in plasma, whose presence was demonstrated in a seminal paper by Mitchell et al. [31] , has been emerging as a potential source of biomarkers for cardiovascular disease [32] , [33] . Indeed, they are likely to reflect cell activation and tissue injury and, intriguingly, they could contribute to intercell signaling through a selective release into the systemic circulation, but origin and function remains poorly understood. They are known to be shed into the extracellular environment in microvesicles (exosomes, microparticles, apoptotic bodies), but the existence of plasma miRNAs in the fraction devoid of microvesicles was demonstrated and explored in several studies. In very recent cardiovascular research, circulating miRNAs have been investigated to gain insights into pathological mechanisms of many diseases as myocardial injury, coronary artery disease, diabetes, and hypertension. As concerns HF, for example, the expression of miR-423-5p [34] was found overexpressed in plasma of patients compared to controls subjects; and, successively, Goren et al. [35] showed that the expression level of a combination of four serum miRNAs could discriminate HF patients compared with healthy subjects. This signature, consisting of upregulated miRNAs with high statistical significance, even if with limited fold change, was shown to correlate with clinical parameters as serum BNP levels and QRS complex width, highlighting a multiscale crosstalk.
2) Long ncRNAs: Among the noncoding RNAs, a novel class of transcripts has been recently emerging for its potential in gene expression regulation: long noncoding RNAs (lncRNAs), whose length is greater than 200 nucleotides, are able to interfere with gene expression through various mechanisms, which still remain largely unknown, at pre-and posttranscriptional level.
The recent transcriptomics studies, thanks to microarrays and especially to next generation sequencing technologies, revealed that lncRNAs are modulated during development and have a key role in cell fate specification. Given their importance in gene transcription program, lncRNAs may play a role in pathophysiology of cardiac disease and specifically in HF [36] . The lncRNA Braveheart, for example, was shown very recently to be essential for cardiovascular lineage commitment [37] and it was found downregulated in plasma of mice in which HF had been induced by isoproterenol infusion. This animal model, which reproduces the cardiotoxic effects of chronic activation of the sympathetic system, was used, indeed, in a recent transcriptome analysis that showed also a unique pattern of circulatory lncRNAs. Specifically, dysregulated lncRNAs in plasma or whole blood were almost double than in heart tissue; moreover, the expression of lncRNAs in heart, whole blood and normal plasma was anticorrelated with transcript length, as expected, whereas this did not hold in HF plasma [38] . These results are suggestive of a potential role of circulatory lncRNAs, as for circulatory miRNAs, in pathogenesis, development and prognosis in HF. Then, a different murine model where pressure overload was surgically (through transaortic constrinction) provoked to induce hypertrophy and subsequently HF, showed the dysregulation of 15 heart tissue lncRNAs [17] . Another intriguing example of lncRNAs action is represented also by the transcript of the gene Kcnq1, which encodes a potassium channel subunit: an lncRNA is contained in one intron able to modulate the expression of the host gene, as demonstrated by Korostowski et al. [39] .
3) Epigenomics: Opportunities of regulation are carried out by the cell also at the level of DNA structural organization. DNA of eukaryotic cells, indeed, is highly condensed in the nucleus to arrange the entire genome sequence. DNA wraps around nucleosomes, complexes of eight histone proteins, as a wire around bobbins. This combination of DNA and proteins, known as chromatin, can exhibit modulated condensation levels: briefly, an open chromatin structure (euchromatin) corresponds to a genomic region which contains expressed genes, whereas a tightly packed conformation (heterochromatin) corresponds to a genomic region which is transcriptionally inactive since it is not exposed to the transcription factors (see Fig. 5 ).
DNA methylation at CpG dinucletotides and histone modifications are processes that influence the DNA structure and, notably, they are also signals which can be acquired, thanks to the new technologies, and processed to add a dimension to the molecular profiling of regulatory mechanisms. These kind of heritable phenomena which act on the genome, altering the packaging but not the sequence, are referred to as epigenomics. Recent studies show that epigenetic mechanisms may play a role in cardiac hypertrophy and failure. For example, Movassagh et al. showed in their recent papers the existence of specific patterns of DNA methylation in human HF which correlate with the expression of genes involved in angiogenesis as PECAM1, ARHGAP24, and AMOTL2 [40] and also found a significant difference of trimethylation of lysine 36 in histone 3 in end-stage HF compared to control subjects [41] .
It has been demonstrated also that hypertrophy can be induced by histone acetyltransferase activity that causes the overexpression of the transcription factor CREB and that it is influenced also by the interference of hyston acetylation with sarcomeric genes [42] .
Very recently, two genes with differential DNA methylation patterns between DCM patients and controls were identified. They have been studied through silencing of their orthologous in zebrafish; this led to a reduced ventricular contractility and subsequent HF, validating the functional role of these genes in the disease development [43] .
III. PROTEOMICS AND METABOLOMICS
If functional genomics delineates the cell program fascinatingly and powerfully going to the upstream phenotype determinants, proteomics technologies must be applied to assess the actual presence and the abundance of the gene products. They allow to cope with the further level of complexity represented by the proteome where co-and post-translational modification events amplify dramatically the number of proteins compared to the number of genes. Many studies concerning cardiac proteomics have been carried out using 2-D gel-based approaches (2-DE) in which proteins are separated along two orthogonal dimensions according to charge and to relative molecular mass and spots of interest are identified by means of mass spectrometry (MS). These 2-D maps need dedicated software for low-level quantification, differential analysis and classification approaches [44] . Due to several limitations in terms of sensitivity and dynamics, gel-free, MS-based proteomics, with its different platforms, has become widely applied. Peptides obtained through sample digestion are separated according to the m/z ratio producing spectra (single-stage spectra for the so-called peptide mass fingerprinting or double-stage spectra for tandem MS implementations) which require adequate computational techniques, also exploiting signal processing methods [45] , which are in continuous evolution, to recover the protein content. A Human Proteomics Organization project, through the effort of an international consortium, has led to the identification, by means of MS-based proteomics, of 3020 proteins annotated as involved in cardiovascular functions; a subset of them (7%) represents a collection of potential marker for HF and cardiac tissue remodeling [46] , [47] .
The protein expression profiling, performed through shotgun proteomics [tandem MS coupled with liquid chromatography (LC), see an example of LC-MS map in Fig. 6.] , of a mouse model of DCM, was proposed by Isserlin et al. [48] comparing cardiac tissue of wild type and transgenic mice at three different times of disease progression [early-stage (8 wk), midstage (16 wk), and end-stage (24 wk)]. The time course experiment allowed to identify many proteins whose expression was dysregulated with HF progression: apoptosis and the MAPK (mitogen-activated protein kinase) cascade were the most significant perturbed pathways.
An interesting study based on 2-DE followed by LC-MS/MS identification, comparing left ventricular tissue lysates of failing and nonfailing human hearts, showed a specific pattern in membrane microdomains for failing hearts [49] ; in Fig. 7 , the reference gel image is reported along with the indication of differentially expressed spots.
A further complement to proteomic strategies is represented by metabolomics which investigates the presence of metabolites as fingerprint of the reactions actually occurring in the system. Also at this level of the information flow, there are evidences about the chance to identify novel biomarkers for HF. In Fig. 8 , two examples of NMR spectra from plasma samples are reported, one for an HF patient and one for a control subject along with the exit of OPLS-DA, which displays the level of discrimination between affected and healthy subjects; the variable importance can then provide the indication about the more discriminant metabolites [50] . IV. HEART RATE VARIABILITY (HRV) AND HF As concerns phenotype assessed at the system level, HRV is a noninvasive quantitative marker of autonomic activity [51] , which is derived from the interbeats series in the ECG (RR series). Interestingly, the regulations of the two main branches of the autonomic nervous system are reflected differently in the RR series [52] . The efferent vagal activity is a major contributor to oscillations having period of about 3-8 beats (the so-called high-frequency range, HF), while sympathetic modulation acts on longer time scales of about 10-30 beats (the low-frequency range, LF). A quantitative assessment through HRV analysis proved immediately effective [53] [54] [55] and a general reduction of HRV was found in HF patients, in apparent contradiction with the increased concentration of norepinephrine in plasma (a measure of sympathetic activation) reported. Possibly, overexpression of tumor necrosis factor and its receptors, which is typical of HF patients, could lead to a loss of adrenergic responsiveness and a subsequent HRV reduction [56] .
Of the several traditional time and frequency methods developed to study HRV [51] , many are linked to all-cause mortality (mostly pump failure) in HF patients, even when corrections for other clinical factors are included. In particular, SDNN (the standard deviation of all normal RR intervals [51] ) and SDANN (the standard deviation of the averages of normal RR intervals in all 5-min segments of the entire recording [51] ), which quantify global HRV variability, and the power in the ultra-and very low frequency band (oscillations with frequency smaller than 0.04 Hz) were found to be independent predictor of mortality [57] . On the contrary, measures describing diminished vagal modulation only, like the power in the high-frequency range, pNN50 (the number of pairs of adjacent normal RR intervals differing by more than 50 ms in the entire recording, divided by the total number of normal RR intervals [51] ) or RMSSD (the square root of the mean of the sum of the squares of differences between adjacent normal RR intervals [51] ), were generally found to bring no additional information.
More interestingly, while an increased sympathetic activity would be expected to produce a relative predominance of LF oscillations, both increased and reduced LF power were found to be associated with an increased risk of cardiac death. However, only a reduced LF power, derived from short-term measures, was consistently found to be an independent predictor of sudden cardiac death in HF patients. In particular, the predictive power was remarkable at night [58] or during controlled breathing [59] , thus removing the potential confounding role of abnormal breathing patterns in the same frequency band. Therefore, despite a significant sympathoexcitation, in HF patients HRV variability is reduced, with low LF power (see Fig. 9 ), possibly due either to reduced responsiveness to chronic sympathetic overactivity [59] or, to a parasympathetic withdrawal.
While LF content in controlled breathing conditions might be the best contribution offered by traditional methods of HRV analysis to sudden death risk stratification, more complex signal processing approaches led to further advances. Such techniques are often termed "nonlinear" either to distinguish them from "linear" spectral analysis, but also as they drew largely from nonlinear dynamical systems theory and nonstationary stochastic processes analysis. Metrics influenced by variability's changes over long time scales proved to be substantially overlapping with clinical and functional risk factors, or with traditional indexes [58] , in the prediction of all-cause mortality [60] . On the contrary short-term HRV nonlinear indexes indeed added prognostic information [57] . In particular, the short-term scaling exponent, obtained from detrended fluctuation analysis, was shown to be an independent predictor of cardiac mortality [61] , more effective than traditional parameters. Also Poincaré (recurrence) plot analysis contributed in providing a marker of increased risk of both all-cause and sudden death which was independent from norepinephrine plasma concentration [62] . However, its computation was based on a qualitative visual evaluation of the Poincaré plot, and further quantitative analysis needs to be performed. Finally, heart rate turbulence, a nonlinear metric of baroreflex sensitivity reflecting the severity of HF [63] , was also shown to be an independent predictor of mortality in HF patients [64] .
V. CONCLUSION
The huge amount of information provided by new highthroughput technologies at different scales requires the development of adequate analytical approaches to effectively exploit the availability of ever more complex "omics" data. Appropriate computational methods are essential both for the lowlevel analysis, to correctly process raw data, and for data mining and modeling. HF can be investigated across different levels of information from molecular profiling, disentangling the networks of key functional elements, to clinical phenotype, assessed with proper indexes at the cardiovascular and systemic level.
The integration of information from different ontologies is essential to make sense of complexity. More holistic models reconciling molecular biology with physiology in a systems biology perspective could really improve HF diagnosis and therapeutic opportunities.
